Latham & Watkins Advises Amgen Inc. in its US$4 Billion Senior Notes Offering

Capital Markets team advised the leading biotechnology company on the offering.

May 07, 2020

Amgen Inc. has announced the closing of an offering of US$1 billion additional principal amount of its 2.200% senior notes due 2027, US$1.25 billion aggregate principal amount of its 2.300% senior notes due 2031, US$750 million additional principal amount of its 3.150% senior notes due 2040 and US$1 billion additional principal amount of its 3.375% senior notes due 2050. The offering of the 2027 notes constitutes a further issuance of Amgen’s 2.200% notes due 2027, of which US$750 million aggregate principal amount was issued on February 21, 2020, the offering of the 2040 notes constitutes a further issuance of Amgen’s 3.150% notes due 2040, of which US$1.25 billion aggregate principal amount was issued on February 21, 2020, and the offering of the 2050 notes constitutes a further issuance of Amgen’s 3.375% notes due 2050, of which US$1.25 billion aggregate principal amount was issued on February 21, 2020. The offering of the notes closed on May 6, 2020. 

Latham & Watkins LLP represented Amgen in the transaction with a corporate team led by Orange County/New York partner Charles Ruck, New York partner Greg Rodgers and Washington, D.C. counsel Chuck Cassidy, with Washington, D.C. associates Paul Alexander and Joe Altieri. Advice was also provided on tax matters by New York partners Jiyeon Lee-Lim and Jocelyn Noll, with New York associates Aaron Bernstein and Michael Syku.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.